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Abstract 
Antibiotic resistant bacteria are becoming an increasing threat worldwide, particularly in the 
healthcare setting. This has led researchers and healthcare providers to begin looking elsewhere 
for solutions. Research suggests that curcumin, a phenolic compound from the spice turmeric, 
has antibacterial properties that may be able to treat potentially life-threatening hospital 
infections, such as those caused by Staphylococcus aureus and Pseudomonas aeruginosa. 
Turmeric has been used in Asian medicine for thousands of years as a general antimicrobial. 
Curcumin was utilized in this study, along with hispolon, another phenolic compound isolated 
from various mushrooms, such as Inonotus hispidus and Phellinus linteus, a medicinal 
mushroom. There is less prior data on hispolon as an antibacterial agent, but it has been found to 
be a potentially effective antiviral and antitumor treatment. Promising research done so far with 
hispolon as an antitubercular drug suggests that it may have some antibacterial properties as 
well. In this study, curcumin, hispolon mono methylether (HME), and hispolon pyrazole (HP) 
were tested on Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis, 
Escherichia coli, and Mycobacterium smegmatis. The results obtained through colony forming 
unit assays, % inhibition calculations, growth curves, biofilm assays, and live-dead fluorescent 
microscopy suggest that HME has significant antibacterial effects on all of the microorganisms 
used except for E. faecalis, where the effects are only moderate, while curcumin has moderate 
antibacterial effects on all but M. smegmatis. HP did not have strong antibacterial effects on 
gram positive or gram negative bacteria, and only seemed to be effective against M. smegmatis. 
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1. Introduction 
Many kinds of bacteria are beneficial in various aspects of life. Healthy humans tend to have 
about 1014 bacteria just in their gut alone (Zhang et al., 2015). These bacteria play many 
important roles in health, such as helping with digestion and providing certain nutrients (Zhang 
et al., 2015). However, not all bacteria are beneficial, and there is a significant number that can 
cause dangerous illnesses in humans when introduced into the body. Bacterial infections have 
been a problem for people for as long as humans have existed, and they can be caused by various 
type of pathogenic bacteria. 
Pathogenicity 
 
There are many factors that make certain bacteria pathogenic. Many bacteria produce toxins, 
such as the lipopolysaccharide endotoxin in gram negative bacteria and teichoic acid in gram 
positive bacteria (Wilson et al., 2002). Toxins are generally classified into different categories, 
including A-B toxins, commonly produced by gram negative bacteria such as Escherichia coli, 
and toxins that form pores in host cell membranes (Wilson et al., 2002). Some pathogenic 
bacteria are enclosed in capsules. These give them extra protection from destruction by 
macrophages in the host immune system, making it easier for these bacteria to evade host 
defenses (Wilson et al., 2002). The cell wall can also determine different virulence factors. As 
previously mentioned, most bacteria are classified as gram negative or gram positive, depending 
on the peptidoglycan composition in their cell wall (Wilson et al., 2002). Some bacteria also 
have the ability to break down host tissues in order to invade them. Staphylococcus aureus is an 
example of a pathogenic bacterium that uses this method, and once the tissues are invaded, it is 
easier for the bacteria to spread to other areas of the body, which then puts the host at risk for 
sepsis (Wilson et al., 2002). There are many mechanisms that pathogenic bacteria use to evade 
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the host immune system and successfully cause disease. Therefore, there need to be treatments to 
either kill these bacteria, or help the immune system eliminate them from the body (Figure 1). 
 
 
Figure 1. Some features that contribute to pathogenicity in bacteria (Wilson et al., 2002) 
 
Antibacterial Treatments 
 
Since the discovery of penicillin as an antibacterial agent by Alexander Fleming, antibacterial 
compounds called antibiotics have been an effective treatment for many bacterial infections 
(Lobanovska & Pilla, 2017). The mode of action for this particular antibiotic is to prevent 
peptidoglycan formation, which can then potentially result in the bacterial cell bursting 
(Lobanovska & Pilla, 2017). The discovery of penicillin has led to the development of other 
antibiotics over time, since different bacteria are susceptible to different ones. For example, gram 
positive and gram negative bacteria may respond differently to various antibacterial compounds 
(Lobanovska & Pilla, 2017). Some of these antibiotics include quinolones, which block bacterial 
DNA replication, aminoglycosides, which inhibit the 30S ribosomal subunit, and macrolides, 
which prevent protein synthesis (Kapoor et al., 2017). There are currently many different 
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antibiotics used in modern medicine that have a wide range of actions against pathogenic 
bacteria (Figure 2). Unfortunately, despite the fact that antibiotics have been in use for less than 
one hundred years, they are quickly becoming less effective. 
 
Figure 2. Various modes of action of different antibiotics (Kapoor et al., 2017) 
 
Antibiotic Resistance 
 
Bacteria that are no longer responding to various types of antibiotics are a growing problem in 
the medical field, leading doctors and scientists to search elsewhere for a solution. Unfortunately, 
a fairly wide range of bacteria are becoming antibiotic resistant, including those that are both 
gram positive and gram negative (Tyagi et al., 2015). In hospitals, where these super bug 
infections are especially a concern, bacteria such as Pseudomonas aeruginosa and 
Staphylococcus aureus are becoming an increasing problem (Tyagi et al., 2015). Bacterial 
infections that can no longer be treated with antibiotics pose a serious threat to future humans. 
The rise in antibiotic resistance has been attributed mainly to over prescribing antibiotics, as well 
as people misusing them, such as stopping the medication before instructed by their physician 
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(Ventola, 2015). Scientists project that by the year 2050, as many as 10 million people each year 
could die from infections caused by antibiotic resistant bacteria (Banin et al., 2017). This issue 
has led researchers to begin investigating other potential antibacterial compounds to eventually 
treat some of these infections. 
There are various mechanisms that different bacteria use to become resistant to antibiotics. 
Gram negative bacteria are generally more resistant to antibacterial agents than gram positive 
bacteria due to the fact that they have an extra cell wall (Zgurskaya et al., 2015). A fairly 
common mechanism that leads to antibiotic resistance is horizontal gene transfer (HGT), where 
one bacterium receives foreign segments of DNA from a different bacterium (Munita & Arias, 
2016). Through this, a gene for resistance to certain antibiotics can be passed on to bacteria that 
did not previously have them. HGT is a major reason for evolution in bacteria as well (Munita & 
Arias, 2016). Gram negative bacteria do have some mechanisms that are different from gram 
positive bacteria. Many gram negative bacteria have started producing enzymes known as β- 
lactamases, which can break down β-lactam rings in certain antibiotics, while a common reason 
for antibiotic resistance in gram positive bacteria includes them modifying sites where antibiotics 
would normally bind (Munita & Arias, 2016). In addition to these methods, gram negative and 
gram positive bacteria both may have efflux pumps, which they can use to quickly pump the 
antibiotics out of the cell before it can be killed (Munita & Arias, 2016) (Figure 3). Therefore, 
regardless of gram classification, antibiotic resistance is becoming a very significant issue 
worldwide. 
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Figure 3. A visual representation of various efflux pumps used in gram positive and gram 
negative bacteria (Munita & Arias, 2016). 
 
 
 
Antibiotic resistance is also a growing problem in Mycobacterium tuberculosis, which is acid- 
fast instead of gram positive or negative (Balaji et al., 2016). Acid-fast positive bacteria, like 
gram positive and gram negative bacteria, do have peptidoglycan in their cell wall (Alderwick et 
al., 2015). However, this is not the main component of their cell wall. Acid-fast cell walls are set 
apart by the large number of mycolic acids they contain, making the cell wall thick, waxy, and 
difficult for various drugs to permeate (Takayama et al., 2005, Smith et al., 2013). Gram positive 
bacteria have a thick peptidoglycan cell wall, while gram negative bacteria have only a thin layer 
of peptidoglycan but also an additional membrane that assists them in drug resistance (Mai- 
Prochnow et al., 2016). The ability for bacteria to develop methods for antibiotic resistance 
regardless of cell wall composition shows what a truly widespread problem this is. In 
comparison to gram negative and gram positive bacteria, there is already a limited range of 
antibiotics that can treat diseases caused by acid-fast bacteria, such as tuberculosis (Smith et al., 
2013). Horizontal gene transfer is also a common way for acid-fast bacteria like M. tuberculosis 
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to become antibiotic resistant, as well as the very slow passage of antibacterial molecules 
through the very thick cell wall (Smith et al., 2013). These bacteria can also modify drugs to 
make them less harmful, as well as using various enzymes to break them down. The particularly 
thick cell wall of acid-fast bacteria already makes it difficult for most antibiotics to permeate 
(Smith et al., 2013). These many mechanisms of antibiotic resistance make it clear that disease 
causing acid-fast bacteria are just as much of an increasing problem as gram negative and gram 
positive bacteria are. 
Staphylococcus aureus 
 
Staphylococcus aureus (S. aureus) is a gram positive coccus that can cause significant 
infections, such as sepsis and infective endocarditis (Teow et al., 2016). These bacteria are 
currently most well-known for its growing resistance to many types of antibiotics and its ability 
to cause deadly skin infections (Teow et al., 2016). S. aureus related diseases that are difficult to 
treat with antibiotics are becoming an increasing problem in healthcare settings, specifically 
methicillin-resistant Staphylococcus aureus (MRSA) (Kong et al., 2016). Many strains of S. 
aureus are also exhibiting resistance to the antibiotic vancomycin (McGuinness et al., 2017). 
Unfortunately, in addition to the strains of S. aureus resistant to one specific drug, there are also 
numerous strains that are multidrug resistant, making them extremely possible to treat and the 
infections they cause very life-threatening (Onanuga & Temedie, 2011). The lack of response 
this pathogen has to certain antibiotics is leading healthcare professionals to start to look 
elsewhere for treatments. MRSA is transmittable from person to person, and based on recent 
studies, has been found to be evolving at a fast rate (Kong et al., 2016). Due to its growing threat 
to the world, S. aureus is a popular target for research. 
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Figure 4. Gram Stain of Gram Positive Coccus Staphylococcus aureus (Aponte 2018) 
 
 
 
 
Enterococcus faecalis 
 
Enterococcus faecalis (E. faecalis) is a gram positive coccus that can be found in the gut as 
part of normal flora of many organisms, including mammals (Van Tyne et al., 2013). Due to 
shedding through feces, E. faecalis can also be found in nature, although it prefers environments 
that are low in oxygen, such as the intestines (Van Tyne et al., 2013). However, as in the case of 
other types of bacteria, overuse of antibiotics has resulted in E. faecalis becoming a growing 
health threat. Virulent strains of E. faecalis are currently one of the main causes of multidrug 
resistant infections, such as bacteremia. These infections are made more dangerous by the 
presence of an exotoxin called cytolysin, which can burst the cells of the host (Van Tyne et al., 
2013). Since E. faecalis is becoming more resistant to traditional antibiotics, it is also often 
included in research searching for new antibacterial treatments. 
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Figure 5. Gram Stain of Gram Positive Coccus Enterococcus faecalis (Aponte 2018) 
 
Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa (P. aeruginosa) is a gram negative bacillus often found in soil 
(Gellatly & Hancock, 2013). It also can cause various infections in humans, and these infections 
are growing increasingly difficult to treat with current antibiotics. Like other difficult to treat 
infections, pseudomonal infections are especially a threat in healthcare settings (Gellatly & 
Hancock, 2013). Some of these infections include bacteremia, ear infections, and, most 
commonly, respiratory tract infections (Gellatly & Hancock, 2013). The respiratory infections 
are considered highly dangerous, but unfortunately are difficult to treat. P. aeruginosa also has 
the ability to form biofilms that are difficult to break up. Researchers are looking for treatments 
that will affect quorum sensing and virulence genes (Gellatly & Hancock, 2013). Drug resistance 
in P. aeruginosa is mainly due to a poorly permeable outer membrane (Gellatly & Hancock, 
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2013). 
 
 
Figure 6. Gram Stain of Gram Negative Bacillus Pseudomonas aeruginosa (Aponte 2018) 
 
Escherichia coli 
 
Escherichia coli (E. coli) is a gram negative bacillus that is very commonly found in the 
healthy gut of humans (Jang et al., 2017). However, certain strains are also associated with 
gastrointestinal illnesses in humans. The most well-known E. coli serovar is O157:H7, which is 
often in the news for severe food poisoning cases that result in stomach cramping, vomiting, and 
bloody diarrhea (Jang et al., 2017). While food is a common source of pathogenic E. coli, water 
can contain the bacteria as well. When testing water quality, the presence or absence of E. coli is 
used to determine whether or not the water is contaminated with feces (Jang et al., 2017). Like 
many other types of bacteria in recent years, E. coli has been developing resistance to many of 
the commonly used antibiotics. This is mainly due to the fact that E. coli found within the gut is 
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subject to the antibiotics consumed by their host (Jang et al., 2017). This poses a threat to human 
health and is leading researchers to look for new antibacterial treatments. 
 
 
Figure 7. Gram Stain of Gram Negative Bacillus Escherichia coli (Aponte 2018) 
 
Mycobacterium smegmatis 
 
Mycobacterium smegmatis (M. smegmatis) is an acid-fast bacteria that does not take up any 
regular gram staining dyes due to its extremely waxy cell membrane, a result of the presence of 
mycolic acids (Wu et al., 2018). M. smegmatis is the less dangerous relative of M. tuberculosis, 
the causative agent of tuberculosis (Smith, 2003). Researchers can use M. smegmatis as a safer 
way to learn about M. tuberculosis. However, it is important to note that they are different from 
one another. M. smegmatis has become a research target because of the growing incidence of 
antibiotic resistance in cases of tuberculosis (Sotgiu et al., 2015). This is making it necessary for 
new anti-tubercular drugs to be discovered. 
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Figure 8: Acid-fast Stain of Acid-fast Positive Bacillus Mycobacterium smegmatis (Aponte 
2018) 
Curcumin 
 
A compound that has provided promising results in terms of being a future antibacterial agent 
is curcumin, a polyphenolic compound that comes from the spice turmeric (Tyagi et al., 2015) 
(Figure 9). Turmeric can be consumed and is often used in various foods or mixed into liquids, 
such as teas. Turmeric is a rhizome, and its scientific name is Curcuma longa (Tyagi et al., 
2015). Records show that people have been using this rhizome as a broad antimicrobial for quite 
a long time, and that it does have potential antifungal, antibacterial, and antiviral activity 
(Moghadamtousi et al., 2014). The earliest known use of turmeric as an herbal medicine goes as 
far back as about 4000 years ago, where it was used in India. Eventually its use spread 
throughout Asia, and it was a popular spice in trading (Prasad & Aggarwal, 2011). The antiviral 
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properties of curcumin have been thoroughly investigated, and it has been determined to work 
against several viruses. Some of these include human immunodeficiency virus (HIV), where 
curcumin is believed to inhibit viral replication, and herpes simplex virus 1 (HSV-1), where host 
cells treated with curcumin are less vulnerable to infection (Kutluay et al., 2008, Flores et al., 
2016). Now, scientists look to determine just how effective curcumin can be on different types of 
drug resistant bacteria. 
 
 
Figure 9. Structure of a Curcumin Molecule (Moghadamtousi et al., 2014) 
 
 
 
Currently, methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to 
patients who are hospitalized (Gupta et al., 2015). This illness has a very high mortality rate, 
leaving healthcare professionals and researchers desperate for another solution. Staphylococcus 
aureus that is resistant to antibiotic treatment is thought to be one of the most common causes of 
infection in the United States (Green et al., 2012). Fortunately, research so far has found 
curcumin to be especially effective against Staphylococcus aureus, which is incredibly important 
for the future of medicine and the growing issue of antibiotic resistance (Teow et al., 2016). 
However, much further research is needed before curcumin is ready to be tested as a new 
treatment. This is also the case for a variety of antibiotic resistant bacteria, including 
Enterococcus faecalis, Pseudomonas aeruginosa, and Escherichia coli, which have all been 
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found to be susceptible to curcumin so far (Tyagi et al., 2015). It has been determined that 
curcumin’s mode of action in both gram positive and gram negative bacteria is to compromise 
the bacterial membrane, killing the cell (Tyagi et al., 2015). There is also potential for curcumin 
to be effective against biofilms. Research done with P. aeruginosa, another threat to patients 
staying in a hospital, suggests that curcumin may inhibit genes associated with biofilm 
formation, such as quorum sensing genes (Moghadamtousi et al., 2014). However, it is also 
cautioned that it cannot yet be determined definitively that curcumin is effective against P. 
aeruginosa. Overall, however, research done with curcumin as an antibacterial agent shows 
promising results. 
Hispolon 
 
Hispolon, a compound similar in structure to curcumin with only a difference in one aromatic 
ring, is also being explored by various researchers as a potential antibacterial agent (Ravindran et 
al., 2010). Hispolon is a polyphenolic compound that has been isolated from various mushrooms, 
such as Inonotus hispidus, and the medicinal mushrooms Phellinus linteus and Phellinus 
igniarius (Chethna et al., 2018). It has various derivatives, including hispolon monomethyl ether 
(HME) (Figure 10) and hispolon pyrazole (HP) (Chethna et al., 2018). It is also considered a 
curcuminoid derivative (Amalraj et al., 2016). So far, its role as an antibacterial agent is less 
certain than curcumin. Hispolon is already a known antitumor agent, and it has been suggested to 
have antiviral properties as well (Chethna et al., 2018). Using this compound as a potential 
antitumor drug has been the most researched, with much work still needed in terms of hispolon 
being an antiviral and antibacterial agent. Currently, hispolon has been shown to stop cell 
proliferation and induce apoptosis in a wide variety of cancers (Kim et al., 2016). The 
antibacterial effects of hispolon have not been widely explored, unlike the antibacterial effects of 
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curcumin, especially in terms of how they would work on antibiotic resistant bacteria. However, 
some early research suggests that various hispolon derivatives may be effective against the 
Mycobacterium genus, leaving it as a possible new treatment for tuberculosis in the future (Balaji 
et al., 2016). Despite the similarity in structure of hispolon to curcumin, past studies have not 
found curcumin to be effective against Mycobacterium (Balaji et al., 2016). Currently, the 
hispolon pyrazole derivatives have been found to be especially effective against Mycobacterium, 
likely through preventing synthesis of mycolic acids (Balaji et al., 2019). It is uncertain as to 
whether or not these specific derivatives have another mechanism to make them active against 
gram positive and gram negative bacteria. Hispolon derivatives such as hispolon mono 
methylether are thought to possibly inhibit the production of the enzyme fatty acid synthase II, as 
well as preventing the synthesis of mycolic acid in Mycobacterium (Balaji et al., 2016). This 
could indicate that these derivatives could be active against gram positive and negative bacteria 
to some extent, as well as being active against acid-fast bacteria. 
 
 
Figure 10. Structure of a Hispolon Derivative Hispolon Mono Methylether (Balaji et al., 2016) 
 
Tuberculosis is a very serious respiratory illness that still affects millions of people worldwide 
every year. It is caused by the bacterium Mycobacterium tuberculosis (Sulis et al., 2014). These 
bacteria are highly virulent and often cause an inflammatory response in the lungs, resulting in 
tissue damage. They also have an extremely thick, waxy cell wall, made up of mycolic acid, 
making treatment difficult (Smith, 2003). Current treatment includes a rigorous antibiotic 
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regimen, with some of the antibiotics effective against tuberculosis including isoniazid, rifampin, 
pyrazinamide, kanamycin, and amikacin (Sotgiu et al., 2015). However, despite the wide range 
of antibiotics available, deaths from tuberculosis are still fairly high, suggesting the need for 
different antibacterial agents that may work more effectively. This is why it is significant that 
some research suggests hispolon may be effective against Mycobacterium (Balaji et al., 2016). 
Interestingly enough, even though curcumin is similar in structure, it does not appear to be 
effective against the Mycobacterium genus (Balaji et al., 2016). The true antibacterial effect of 
hispolon derivatives on other bacteria, such as S. aureus, E. faecalis, P. aeruginosa, and E. coli, 
has yet to be determined. 
Biofilms 
 
Biofilms, especially in the healthcare setting, have the ability to be very dangerous to humans. 
Biofilms result from bacteria forming a thick clump on some hard surface and then shielding 
themselves with extracellular matrix (ECM) (Lόpez et al., 2010). The ECM is produced by the 
bacteria in the biofilm and include polysaccharides, proteins, and some DNA (Lόpez et al., 
2010). There are many places biofilms can form, and although some may lead to persistent 
infections in humans, there are some that are not necessarily harmful. An example of a neutral 
biofilm would be in dental plaques (Lόpez et al., 2010). However, there are many cases where 
the formation of biofilms can lead to infections that are difficult to treat. Many biofilms contain 
persister cells, which contain toxins thought to block antibiotics from being effective (Lόpez et 
al., 2010). Therefore, biofilms that contain these non-dividing cells are often resistant to a wide 
range of antimicrobials, making them hard to cure (Lόpez et al., 2010). 
Biofilm bacteria use a process called quorum sensing in order to communicate with one 
another (Høiby et al., 2011). Through quorum sensing they are able to turn on genes that allow 
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for the production of virulence factors, which help make the biofilm more aggressive (Høiby et 
al., 2011). Mutation is also common in biofilms, increasing the probability of antibiotic 
resistance. Unfortunately, biofilms are not only resistant to many antibiotics, but they are often 
able to evade the response by the immune system as well (Høiby et al., 2011). Persister cells are 
considered one main reason why antibiotic resistance occurs. The ECM itself is also thought to 
be a source of antibiotic resistance, suggesting that it prevents effective diffusion of drugs into 
the biofilm (Høiby et al., 2011). Most types of bacteria are able to form biofilms if given the 
proper environment. Pseudomonas aeruginosa, one of the bacteria used in this study, is a 
common cause of biofilms that threaten human health, particularly in cystic fibrosis patients 
(Høiby et al., 2011). P. aeruginosa often causes lung infections in these patients, and it is 
capable of causing skin infections as well (Lόpez et al., 2010). Naturally, biofilms threaten 
health are an area of interest in research as scientists try to identify potential treatments that will 
work more effectively than many of the current antimicrobials. 
There is some evidence that antibiotics used in synergy with other antimicrobial compounds, 
such as curcumin, may be more effective against biofilms than just antibiotics or curcumin alone 
(Kali et al., 2016). Results from this research so far suggest that when antibiotics and curcumin 
are used together, curcumin is able to increase antibiotic susceptibility in biofilms, so then the 
antibiotics are more successful at ending the infection as opposed to when either are working on 
their own (Kali et al., 2016). Instead of current antibiotics being phased out all together, the 
solution may be to just use them along with another antibacterial compound. Examples of this 
have been seen specifically in regard to Staphylococcus aureus. Researchers have looked at the 
use of curcumin and antibiotics together against methicillin resistant Staphylococcus aureus 
(MRSA) strains to see if the curcumin is able to reduce antibiotic resistance (Mun et al., 2013). 
25 
 
S. aureus in particular is an antibiotic resistance threat, making it very popular in research 
looking for new antimicrobials. Thus far research has found that the use of curcumin with 
antibiotics such as quinolones and β-lactams against MRSA does in fact make the bacteria more 
susceptible to the antibiotics by decreasing minimal inhibitory concentration (MIC) (Mun et al., 
2013). It is cautioned that more research in this area is needed, particularly with other resistant 
bacteria besides S. aureus, but early results are promising. 
Mode of Action 
 
The exact mechanisms by which the antibacterial activity of curcumin and hispolon occur are 
still to be determined. Since curcumin has been a much larger antibacterial target in current 
research, scientists do have some ideas as to how this compound stops bacterial growth. 
Currently results show that curcumin may act by causing leaking in the cell membrane, both in 
gram negative and gram positive bacteria (Tyagi et al., 2015). This eventually causes the cell to 
burst and results in death, preventing further reproduction (Tyagi et al., 2015). There is more of a 
question as to exactly how hispolon works in killing bacteria that are not acid-fast. Studies that 
have focused on using hispolon compounds to treat tuberculosis suggest that both hispolon and 
hispolon pyrazole derivatives may target enzymes required to synthesize mycolic acid, which is 
essential in the Mycobacterium cell wall (Balaji et al., 2016, Balaji et al., 2019). If the ability to 
synthesize mycolic acid is hindered, that will prevent the replication of the bacteria. It is thought 
that this is done through inhibiting mtFABH, the Mycobacterium specific version of the beta- 
ketoacyl-synthase III enzyme that plays a role in fatty acid synthesis (Balaji et al., 2016, Brown 
et al., 2005). mtFABH is essential for the synthesis of mycolic acids in acid-fast bacteria, and its 
inhibition would pose a serious problem for replication (Balaji et al., 2016). Studies suggest that 
this is one mode of action by hispolon derivatives, and so far the main mode of action by 
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hispolon pyrazoles (Balaji et al., 2016, Balaji et al., 2019). However, this does not explain the 
mode of action hispolon compounds may have in gram positive and gram negative bacteria, 
since their cell walls are made differently. It has also been suggested that the regular hispolon 
derivatives may block the action of fatty acid synthase II, which could affect fatty acid synthesis 
in all bacteria (Balaji et al., 2016). This is the mode of action of some current antibiotics (Zhang 
et al., 2006). Further research focusing on hispolon compounds as antibacterial agents is needed 
in order to determine its mode of action on these bacteria. 
Objectives of This Study: 
 
1) Determine the antibacterial effects of curcumin on S. aureus, E. faecalis, E. coli, P. 
aeruginosa, and M. smegmatis. 
2) Determine the antibacterial effects of HME on S. aureus, E. faecalis, E. coli, P. aeruginosa, 
 
and M. smegmatis. 
 
3) Determine the antibacterial effects of HP on S. aureus, E. faecalis, E. coli, P. aeruginosa, and 
 
M. smegmatis. 
 
4) Determine if curcumin and HME are effective against biofilms at 50 µM concentrations. 
 
5) Determine if one compound is more effective than the other. 
2. Materials and Methods 
Preparation of Bacterial Cultures: 
Stock cultures of S. aureus, E. faecalis, E. coli, and P. aeruginosa were prepared by 
inoculating 15 ml test tubes of previously prepared Brain Heart Infusion (BHI) broth with pure 
cultures prepared on nutrient agar plates. M. smegmatis stock cultures were prepared by 
inoculating 15 ml test tubes of previously prepared 7H9 neat media with pure cultures prepared 
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on LB CB+CHX agar plates. All tubes were incubated overnight at 37°C. Stock cultures were 
then stored at 4°C. The purity of the cultures was checked periodically. 
Preparation of Curcumin Stock: 
 
A 10X stock solution of curcumin was prepared by dissolving curcumin powder in 
dimethylsulfoxide (DMSO). The stock was wrapped in aluminum foil and stored at 4°C. The 
10X solution was further diluted as required to produce final concentrations of 25 μM, 50 μM, 
and 100 μM. 
Preparation of HME Stock: 
 
A 10X stock solution of HME was prepared by dissolving HME powder in dimethylsulfoxide 
(DMSO). The stock was wrapped in aluminum foil and stored at 4°C. The 10X solution was 
further diluted as required to produce concentrations of 25 μM, 50 μM, and 100 μM. 
Preparation of HP Stock: 
 
A 10X stock solution of HP was prepared by dissolving HP powder in dimethylsulfoxide 
(DMSO). The stock was wrapped in aluminum foil and stored at 4°C. The 10X solution was 
further diluted as required to produce concentrations of 25 μM, 50 μM, and 100 μM. 
DNA Extraction, PCR, and Sequencing to Confirm the Purity of the Cultures 
 
Methods from Lee et al., 2018: In order to determine if the five bacterial cultures were pure and 
correct, polymerase chain reaction (PCR) was performed using 16S forward and reverse primers, 
27F (5’- AGA GTT TGA TCC TGG CTC AG-3’) and 1492R (5’- ACG GCT ACC TTG TTA 
CGA CTT-3’) respectively. The PCR products were then sequenced and the microorganisms 
were determined by BLAST search. DNA extraction was first performed on all five 
microorganisms by adding 500 µl of each bacterium to five separate 1.5 ml microcentrifuge 
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tubes each containing 100 µl of InstaGene. The tubes were vortexed for 30 seconds and then 
placed in a 100°C heating block for ten minutes. After the heating period, tubes were 
immediately placed on ice for one minute and then vortexed for 30 seconds. Tubes were then 
centrifuged at maximum speed for one minute to separate the extracted DNA into the 
supernatant. PCR reaction tubes were then prepared for each of the five microorganisms. To each 
tube, 20 µl of Taq MasterMix, 2 µl of forward primer, 2 µl of reverse primer, 14 µl of nuclease 
free sterile water, and 2 µl of microbial DNA were added for a total volume of 40 µl (Lee et al., 
2018). PCR was completed by the thermalcycler under the following conditions: 95°C for one 
minute for initial denaturation, 25 cycles of 95°C (10 seconds), 55°C (10 seconds), and 72 °C (10 
seconds), and then 72°C for 10 minutes. The PCR products were confirmed through gel 
electrophoresis and samples were sent out for sequencing. Sequences were copy and pasted into 
the BLAST computer program to see if the correct bacteria were isolated. 
Curcumin Colony Forming Unit (CFU) Assay: 
 
Curcumin treatments were prepared from the 10X stock solution by diluting it to the desired 
final concentrations of 25 µM, 50 µM, and 100 µM. Untreated cultures were used as a control. 
Three repeatings were carried out for each condition and each microorganism. For each of the 
microorganisms, 99 µl of bacteria were treated with 1 µl of each of the three concentrations in 
microcentrifuge tubes. Treated bacteria were incubated at room temperature for 2 hours (120 
minutes). Serial dilutions were prepared using 990 μl of water in 1.5 ml microcentrifuge tubes. 
For each dilution, 10 μl of treated bacteria were added to the 990 μl of water.  Final dilutions for 
S. aureus, E. coli, and E. faecalis were 10-4. Final dilutions for P. aeruginosa and M. smegmatis 
 
were 10-6. For each of the 15 samples, 100 μl of each sample was plated onto 15 different 
nutrient agar plates (3 plates for each microorganism: 25 μM, 50 μM, 100 μM). Control plates 
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were prepared for each of the five microorganisms, where serial dilutions were performed as 
mentioned previously and 100 μl of each of the untreated microorganisms were plated on 
previously prepared nutrient agar plates. Final dilutions for S. aureus, E. coli, and E. faecalis, 
were 10-4. Final dilutions for M. smegmatis were 10-6. Final dilutions for P. aeruginosa were 10- 
 
8. All plates were inverted and incubated overnight at 37°C. M. smegmatis plates were incubated 
for an additional 6 days. Colony forming units (CFUs) were counted. There were three 
repeatings for each microorganism. The mean and standard deviation for each microorganism at 
each treatment concentration were obtained to prepare graphs for CFU data. Each of the five 
microorganisms were also treated with 2% DMSO to determine the effect of DMSO at this 
concentration and lower on the bacteria. 
HME Colony Forming Unit (CFU) Assay: 
 
HME treatments were prepared from the 10X stock solution by diluting it to the desired final 
concentrations of 25 µM, 50 µM, and 100 µM. Untreated cultures were used as a control. Three 
repeatings were carried out for each condition and each microorganism. For each of the 
microorganisms, 99 µl of bacteria were treated with 1 µl of each of the three concentrations in 
microcentrifuge tubes. Treated bacteria were incubated at room temperature for 2 hours (120 
minutes). The following procedures are the same as described above. 
HP Colony Forming Unit (CFU) Assay: 
 
Curcumin treatments were prepared from the 10X stock solution by diluting it to the desired 
final concentrations of 25 µM, 50 µM, and 100 µM. Untreated cultures were used as a control. 
Three repeatings were carried out for each condition and each microorganism. For each of the 
microorganisms, 99 µl of bacteria were treated with 1 µl of each of the three concentrations in 
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microcentrifuge tubes. Treated bacteria were incubated at room temperature for 2 hours (120 
minutes). The following procedures are the same as described above. 
% Inhibition Calculations 
 
CFU data collected from all five microorganisms treated with different concentrations of 
curcumin, HME, and HP was averaged to calculate % inhibition using the formula: 
% inhibition= (control-treatment)/control X100. This was calculated for each microorganism 
at each treatment concentration for all three compounds. Values were then graphed to compare 
% inhibition between concentrations and compounds for each of the five microorganisms. 
 
The Effect of Curcumin and HME on the Growth of Microorganisms 
 
Growth curves were performed on S. aureus, E. faecalis, P. aeruginosa, E. coli, and M. 
smegmatis untreated, treated with curcumin (50 µM), and treated with HME (µM). A 48-well 
plate was used, and three repeatings were carried out for each of the five bacteria under each of 
the three conditions (untreated, treated with curcumin, and treated with HME). All bacterial 
samples were diluted with nutrient broth to approximately 0.1 optical density (OD) at 600 nm. 
The growth was monitored for the five microorganisms untreated, treated with 50 μM curcumin, 
and treated with 50 μM HME. To each of these wells, 450 μl of bacteria were added. For the 
untreated, 50 μl of media was added. For the curcumin treated, 50 μl of a 1X curcumin solution 
at a final concentration of 50 μM was added. For the HME treated, 50 μl of a 1X HME solution 
at a final concentration of 50 μM HME was added. The three remaining wells were used for 
negative controls: one with only media (nutrient broth), one with media and curcumin, and one 
with media and HME. Readings were done every hour, starting at 0 hours and going to 10 hours 
using the microplate reader. A final reading was taken after 24 hours. The three repeatings for 
each microorganism under each condition were averaged and graphed on Excel to determine the 
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overall growth over the 10 hour span. Standard deviation was calculated and shown on the graph 
as well. 
Biofilm Evaluation- Congo Red Assay: 
 
A 24-well Congo Red plate was utilized to test curcumin and HME effectiveness on biofilms. 
90 μl of S. aureus, E. faecalis, E. coli, P. aeruginosa, and M. smegmatis were each incubated 
with 10 μl of a 1X curcumin solution (100 μM) at room temperature for two hours. In addition, 
90 μl of S. aureus, E. faecalis, E. coli, P. aeruginosa, and M. smegmatis were each incubated 
with 10 μl of 100 μM HME at room temperature for two hours. Four wells were utilized for each 
microorganism: a negative control, the microorganism without treatment, the microorganism 
treated with 50 μM curcumin for two hours, and the microorganism treated with 50 μM HME for 
two hours. A total of 50 μl of each sample was inoculated into each well. The plate was then 
incubated at 37°C and checked at 24, 48, and 72 hours. 
Biofilm Evaluation- Crystal Violet Assay 
 
For this assay to evaluate action against biofilms, a 48-well plate was prepared. Three 
repeatings were done for each of the five bacteria (S. aureus, E. faecalis, E. coli, P. aeruginosa, 
and M. smegmatis) under each of the three conditions (untreated, treated with curcumin, and 
treated with HME). All bacterial samples were diluted with nutrient broth to approximately 0.1 
optical density (OD). The plate included the five microorganisms untreated, treated with 50 μM 
curcumin, and treated with 50 μM HME. To each of these wells, 450 μl of bacteria were added. 
For the untreated samples, 50 μl of media was added. For the curcumin treated, 50 μl of 50 μM 
curcumin was added. For the HME treated, 50 μl of 50 μM HME was added. The three 
remaining wells were used for negative controls: one with only media (nutrient broth), one with 
media and curcumin, and one with media and HME. The plate was incubated at 37°C for four 
32 
 
days to allow formation of biofilms. On the fourth day, liquid was aspirated from all wells and 
discarded. The wells were washed three times with 250 μl 1X PBS. To each well, 500 μl of 0.1% 
crystal violet was added and allowed to stain for 30 minutes. The crystal violet was removed and 
the wells were washed again with 250 μl 1X PBS. The plate was left at room temperature 
overnight for the stain to dry. Excess stain was wiped up with sterile cotton swabs, and 1 ml of 
30% acetic acid was added to each well. The microplate reader was then used to determine 
optical density at 595 nm for each sample. Averages were taken for each microorganism under 
each of the three conditions. 
Biofilm Evaluation- Resazurin Assay 
 
For this assay to evaluate biofilms, 48-well plate was used, and three repeatings were done for 
each of the five bacteria under each of the three conditions (untreated, treated with curcumin, and 
treated with HME). All bacterial samples were diluted with nutrient broth to approximately 0.1 
optical density (OD). This growth curve included the five microorganisms untreated, treated with 
50 μM curcumin, and treated with 50 μM HME. To each of these wells, 450 μl of bacteria were 
added. For the untreated, 50 μl of media was added. For the curcumin treated, 50 μl of a 1X 
curcumin solution at a final concentration of 50 μM was added. For the HME treated, 50 μl of a 
1X HME solution at a final concentration of 50 μM was added. The three remaining wells were 
used for negative controls: one with only media (nutrient broth), one with media and curcumin, 
and one with media and HME. The plate was incubated at 37°C and 5% CO2 for four days in 
order to allow biofilms to grow. After the four days, the liquid was aspirated from each well and 
discarded. Each well was washed three times with 250 μl 1X PBS. An additional 200 μl 1X PBS 
was added to each well, along with 200 μl of 20 μM Resazurin. The plate was wrapped in 
aluminum foil and placed at 4°C overnight. The microplate reader was then used to measure 
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excitation at 560 nm and emission at 590 nm. Averages were taken for each microorganism 
under each of the three conditions. 
Live-Dead Assay Using Fluorescent Microscopy 
 
Stock plates were prepared for all five microorganisms on nutrient agar plates. To prepare 
treatment tubes, colonies from the plates were added to 1.5 ml microcentrifuge tubes, 
resuspended in 5 µl of nutrient broth, and treated with 2 µl of of a 1X curcumin or HME solution 
at a final concentration of 50 μM for two hours. To prepare the control slides, a loopful of 
bacteria was taken from the plate for each of the five microorganisms and smeared on the slide. 
Following this step, 5 µl of 60 Red: 40 Green Live-Dead dye was added directly over the 
bacterial sample on the slide. For the treatment slides for both curcumin and HME, 5 µl of the 
treated bacteria were added to the slide, along with 5 µl of Syto®9-Green and Propidium iodide- 
Red (live-dead dye). All slides were allowed to dry before being focused under the fluorescent 
microscope and imaged at 40X. This was done for all five microorganisms including a control 
slide, a curcumin treated slide, and an HME treated slide. 
3. Results and Discussion 
 
Bacterial Purity and Species Determination 
 
Following DNA extraction and PCR of each of the five bacteria used in this study, the PCR 
products were sequences. The sequences obtained were run through the BLAST computer 
program at the NCBI website in order to determine if the stock samples were pure and correct. 
Sequencing determined that the proper microorganisms were in fact being used (Figures 11-15). 
Figure 11: BLAST Sequencing Results for S. aureus 
CCCAATAATTCCGGATAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGT 
TAGCCGTGGCTTTCTGATTAGGTACCGTCAAAATGTGCACAGTTACTTACACATATGTTCTTCCC 
TAATAACAGAGTTTTACGATCCGAAGACCTTCATCACTCACGCGGCGTTGCTCCGTCAGGCTTTC 
GCCCATTGCGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTCTGGACCGTGTCTCAGTTCCAG 
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TGTGGCCGATCACCCTCTCAGGTCGGCTATGCATCGTTGCCTTGGTAAGCCGTTACCTTACCAAC 
TAGCTAATGCAGCGCGGATCCATCTATAAGTGACAGCAAGACCGTCTTTCACTTTTGAACCATGC 
GGTTCAAAATATTATCCGGTATTAGCTCCGGTTTCCCGAAGTTATCCCAGTCTTATAGGTAGGTT 
ATCCACGTGTTAC GCTTCTCTGATGTTAGCGGCGGACGGGTGAGTAACACGTGG 
ATAACCTACCTATAAGACTGGGATAACTTCGGGAAACCGGAGCTAATACCGGATAATATTTTGAA 
CCGCATGGTTCAAAAGTGAAAGACGGTCTTGCTGTCACTTATAGATGGATCCGCGCTGCATTAG 
CTAGTTGGTAAGGTAACGGCTTACCAAGGCAACGATGCATAGCCGACCTGAGAGGGTGATCGGC 
CACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCGCAAT 
GGGCGAAAGCCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTCTTCGGATCGTAAAACTCTG 
 
Figure 11. Staphylococcus aureus sequence (via NCBI, blast.ncbi.nlm.nih.gov). 
 
Figure 12: BLAST Sequencing Results for E. faecalis 
GTTACCGGGGCTGATCTGCGAGTCGTACGCTTCTTTCCTCCCGAGTGCTTGCACTCAATTGGAG 
AGAGGAGTGGCGGCCGGGCGAGTATCACGTATGCGGCCTACCCATCAGAGCGGGATTACACTT 
GGAAACAGATGCTTATACCGCATAACAGTTTATGCCGCATGCCATATGAGTGAAAGGCGCTTTC 
GGGTGTCGCTGATGGATGGCCCCGCGGTGCATTAGCTAGTTGGTGAGATAACGGCTCACCAAGG 
CCACCATGCATAGCCGACCTGAAACAGGATTCAACTCTACTGGGACTGACACAGGGTTGAGACT 
CCTACGGGAGGCAGCAGTAGGGAATCTTCGGCAATGGACGAAAGTCTGACCGAGCAACGCCGC 
GTGAGTGAAGAAGACATTCGGATCGTAAAACTCTGTTGTTAGAGAAGAACAAGGACGTTACTGA 
CCTGAACGTCCCCTGACGGTATCTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGG 
GCAATACGTACGGAGGCAAGCGTTGTGCTGGATTTGATTGGGCGTAAAGCGAGCGCATGGCGT 
GTGACTTACGTCTGATGTGACAGCACTCCGGCTTCAACCGGTGCAGGATCATTGTACACTCAGC 
ACACTAGAGTGCAACACGAGGCAGAGTGGTATTCACATGATGCTAGCGACTGGAAATGGCACTA 
CCTAGTGATGGTAGGGATCACGGGTTGGCTGCACCGACGGCTTCTCTAGGCTCTGGATAACCTC 
GGACTGCCTGAAGACCTACGAAAAGGCCGTGGTTCAGCAACTGAGGGATTTCAGTATAACCCTT 
GGCTAGGTCAATCGTCAGTAGAACGGAATGGTGGGACTAACGTGGTTCTTGCCATGCGTTCTGC 
CGACTTCTATAGCAGTTGGCCTAGCAGTCAAACTGCAACTCCATGCCACGTGCCTGCACTGGCG 
GGAGATAACTGTATACTCAGCTACACAGAGATTCGCTCA 
Figure 12. Enterococcus faecalis sequence (via NCBI, blast.ncbi.nlm.nih.gov). 
 
Figure 13: BLAST Sequencing Results for E. coli 
CAGCACCAGCTACCATGCAGTCGACGGTACAGGAGCAGCTTGCTGCTTCGCTGACGAGTGGCGG 
ACGGGTGAGTAATGTCTGGGAAACTGCCTGATGGAGGGGGATAACTACTGGAAACGGTAGCTAA 
TACCGCATAACGTCGCAAGACCAAAGAGGGGGACCTTCGGGCCTCTTGCCATCGGATGTGCCCA 
GATGGGATTAGCTAGTAGGTGGGGTAACGGCTCACCTAGGCGACGATCCCTAGCTGGTCTGAGA 
GGATGACCAGCCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGA 
ATATTGCACAATGGGCGCAAGCCTGATGCAGCCATGCCGCGTGTATGAAGAAGGCCTTCGGGTT 
GTAAAGTACTTTCAGCGGGGAGGAAGGGAGTAAAGTTAATACCTTTGCTCATTGACGTTACCCG 
CAGAAGAAGCACCGGCTAACTCCGTGCCAGCAGCCGCGGTAATACGGAGGGTGCAAGCGTTAA 
TCGGAATTACTGGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCAGATGTGAAATCCCCGGGC 
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TCAACCTGGGGAACTGCATCTGATACTGGCAAGCTTGAGTCTCGTAGAGGGGGGGTAGAATTCC 
AGGTGTAGCGGTGAAATGCGTAGAGATCTGGAGGAATACCGGTGGCGAAGGCGGCCCCCTGCA 
CGAAGACTGACGCTCAAGGTGCGAAAGCGTGGCGAGCAAACAGGATTAGATACCCTGGGTAGTT 
CCACGCCGTAAAACGATGTCGACTTGGGAGGTTTGTGCCCTTGAGGCGTGCCTTCCGGGAGCTA 
ACGCGTTTAAGTCGACCGCCATGGCGGAAGTACGGCTGCAAGGCCTAAAAACTTCTAACTGTAA 
TGGAACTGGAGGGGAACTGCACAACCTCTGT 
Figure 13. Escherichia coli sequence (via NCBI, blast.ncbi.nlm.nih.gov). 
 
Figure 14: BLAST Sequencing Results for P. aeruginosa 
CGGGGGACAGCTACACATGCAGTCGAGCGGAGAAGGGAGCTTGCTCCTGGATTCAGCGGCGGA 
CGGGTGAGTAATGCCTAGGAATCTCGCCTGGTAGTGGGGGATAACGTCCGGAAACGGGCGCTA 
ATACCGCATACGTCCTGAGGGAGAAAGTGGGGGATCTTCGGACCTCACGCTATCAGATGAGCCT 
AGGTCGGATTAGCTAGTTGGTGGGGTAAAGGCCTACCAAGGCGACGATCCGTAACTGGTCTGAG 
AGGATGATCAGTCACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGG 
AATATTGGACAATGGGCGAAAGCCTGATCCAGCCATGCCGCGTGTGTGAAGAAGGTCTTCGGAT 
TGTAAAGCACTTTAAGTTGGGAGGAAGGGCAGTAAGTTAATACCTTGCTGTTTTGACGTTACCAA 
CAGAATAAGCACCGGCTAACTTCGTGCCAGCAGCCGCGGTAATACGAAGGGTGCAAGCGTTAAT 
CGGAATTACTGGGCGTAAAGCGCGCGTAGGTGGTTTCAGCAAGTTGGATGTGAAATCCCCGGGC 
TCAAACCTGGGAACTGCATCCCAAAACTACTGAGCTAGAGTACGGGTAGAGGGTGGTGGAATTT 
CCCTGTGTAGCCGGTGAAATGCGTAGAATAATAGGTAGGAACATCCAGTGTCGGAAGCGACCAC 
CTTGGACTGATACCTGACACTGAAGTGGGCGAAAGCGTGGGGAGCAACAGAATAGATACCTTGC 
TAGTCCACGCCGTAACGATGTCCGACTAGTCGTCGGAATCCTGGAACTTTATGCGCAGCTTAAC 
GCATAGTGCACCGCTGGTATACGTCGCAGGGGTTTAC 
 
Figure 14. P. aeruginosa sequence (via NCBI, blast.ncbi.nlm.nih.gov). 
Figure 15: BLAST Sequencing Results for M. smegmatis 
CTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGC 
AAGCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAC 
AGACGAAGCGCAAGTGACGGTATGTGCAGAAGAAGGACCGGCCAACTACGTGCCAGCAGCCGC 
GGTAATACGTAGGGTCCGAGCGTTGTCCGGAATTACTGGGCGTAAAGAGCTCGTAGGTGGTTTG 
TCGCGTTGTTCGTGAAAACTCACAGCTTAACTGTGGGCGTGCGGGCGATACGGGCAGACTAGAG 
TACTGCAGGGGAGACTGGAATTCCTGGTGTAGCGGTGGAATGCGCAGATATCAGGAGGAACAC 
CGGTGGCGAAGGCGGGTCTCTGGGCAGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAA 
CAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGGTGGGTACTAGGTGTGGGTTTCCTTCCT 
TGGGATCCGTGCCGTAGCTAACGCATTAAGTACCCCGCCTGGGGAGTACGGCCGCAAGGCTAAA 
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ACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGTGGATTAATTCGATGCAACG 
CGAAGAACCTTACCTGGGTTTGACATGCACAGGACGCCGGCAGAGATGTCGGTTCCCTTGTGGC 
CTGTGTGCAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCA 
ACGAGCGCAACCCTTGTCTCATGTTGCCAGCACGTTATGGTGGGGACTCGTGAGAGACTGCCGG 
GGTCAACTCGGAGGAAGGTGGGGATGACGTCAAGTCATC 
Figure 15. M. smegmatis sequence (via NCBI, blast.ncbi.nlm.nih.gov). 
Screening Effectiveness of Curcumin on Bacterial Cells by CFU Assays 
 
To determine whether or not curcumin would be at all effective against the various types of 
bacteria used in this study, each of the five microorganisms were initially treated with varying 
concentrations of curcumin (25 μM, 50 μM, and 100 μM) for two hours (120 minutes) at room 
temperature. The plates were incubated overnight, and colonies were counted on each plate, 
including all control and treated plates. This was repeated for each microorganism three times. 
The results indicated that limited colonies were seen on treated S. aureus, E. faecalis, P. 
aeruginosa, and E. coli for all concentrations compared to all control plates. M. smegmatis did 
not seem to be inhibited by curcumin (Figure 16). These results suggest that curcumin is 
effective against four of the five studied microorganisms, and that acid-fast bacteria may be 
resistant to curcumin treatment. 
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Screening Effectiveness of HME on Bacterial Cells by CFU Assays 
 
In order to determine whether or not hispolon would also be effective against the various types 
Figure 16: Treatment of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, and 
Mycobacterium smegmatis with Varying Concentrations of Curcumin 
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Figure 16. Treatment with curcumin for two hours at room temperature was done on Staphylococcus aureus (A), Enterococcus 
faecalis (B), Pseudomonas aeruginosa (C), Escherichia coli (D), and Mycobacterium smegmatis (E) to determine the effectiveness 
of the compound as an antibacterial agent. 
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of bacteria used in this study, each of the five microorganisms were initially treated with varying 
concentrations of HME (25 μM, 50 μM, and 100 μM) for two hours (120 minutes) at room 
temperature. The plates were incubated overnight and then compared to control plates to 
determine whether or not HME inhibited bacterial growth. A colony forming unit (CFU) assay 
was performed and colonies were counted on each plate, including all control and treated plates. 
This was repeated for each bacteria 3 times. Limited growth was seen on all treated bacteria at all 
concentrations: S. aureus, E. faecalis, P. aeruginosa, E. coli. and M. smegmatis (Figure 17). 
These results suggest that HME is potentially effective in preventing the growth of all five 
microorganisms used in this study. 
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Figure 17: Treatment of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, 
Escherichia coli, and Mycobacterium smegmatis with Varying Concentrations of HME 
A B 
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Figure 17. Treatment with hispolon-2 for two hours at room temperature was done on Staphylococcus aureus (A), 
Enterococcus faecalis (B), Pseudomonas aeruginosa (C), Escherichia coli (D), and Mycobacterium smegmatis (E) to 
determine the effectiveness of the compound as an antibacterial agent. 
Screening Effectiveness of HP on Bacterial Cells by CFU Assays 
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To determine if another hispolon derivative, hispolon pyrazole (HP), was effective against the 
various types of bacteria used in this study, each of the five microorganisms were initially treated 
with varying concentrations of HP (25 μM, 50 μM, and 100 μM) for two hours (120 minutes) at 
room temperature. The plates were incubated overnight and then compared to control plates to 
determine whether or not HP inhibited bacterial growth. A colony forming unit (CFU) assay was 
performed and colonies were counted on each plate, including all control and treated plates. This 
was repeated for each bacteria 3 times. This compound did not appear to significantly inhibit S. 
aureus, E. faecalis, E. coli, and P. aeruginosa, since treated plates had almost as many, if not 
more, colonies than control plates. Only M. smegmatis was significantly inhibited by this 
compound (Figure 18). These results suggest that HP is not as effective as HME in preventing 
bacterial growth, with the exception of M. smegmatis. 
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Figure 18. Treatment of Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, 
Escherichia coli, and Mycobacterium smegmatis with Varying Concentrations of HP 
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Figure 18. Treatment with HP for two hours at room temperature was done on Staphylococcus aureus (A), Enterococcus 
faecalis (B), Pseudomonas aeruginosa (C), Escherichia coli (D), and Mycobacterium smegmatis (E) to determine the 
effectiveness of the compound as an antibacterial agent. 
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Colony Forming Unit (CFU) Assay Graphs for Curcumin, HME, and HP 
 
All CFU data collected from control plates as well as curcumin, HME, and HP treated plates 
were averaged and converted into graphs comparing colony forming units among control plates, 
25 μM treated plates, 50 μM treated plates, and 100 μM treated plates for each microorganism. 
CFU data for each microorganism treated with each compound was graphed separately. When 
comparing CFU data for bacteria treated with curcumin (Figure 19) and bacteria treated with 
HME (Figure 20), it was determined that bacteria treated with curcumin tended to have fewer 
CFUs than bacteria treated with HME. Both compounds worked extremely well against S. 
aureus in particular (Figure 19A, Figure 20A), with average growth of 45 CFUs/104 for control 
plates and average CFUs of less than one for curcumin treated plates. HME treated plates all had 
average CFUs two or lower. Both treatments also worked exceptionally well on P. aeruginosa. 
For all bacteria treated with both compounds besides M. smegmatis treated with curcumin, 
treated plates at all three concentrations had fewer CFUs than control plates. However, HP was 
considerably less successful against S. aureus, E. faecalis, E. coli, and P. aeruginosa, with 
treated plates having almost as many, and in some cases more, CFUs than the control plates 
(Figure 21). However, HP did seem to be effective against M. smegmatis, which had hundreds of 
colonies on the control plates and averages below two hundred on all of the treated plates. 
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Figure 19: CFUs for Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, 
Escherichia coli, and Mycobacterium smegmatis Treated with Curcumin 
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Figure 19. Colony Forming Units (CFUs) for Staphylococcus aureus (A), Enterococcus faecalis (B), Escherichia coli (C), 
Pseudomonas aeruginosa (D), and Mycobacterium smegmatis (E) treated for two hours with varying concentrations of curcumin. 
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Figure 20: CFUs for Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, 
Escherichia coli, and Mycobacterium smegmatis Treated with HME 
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Figure 20. Colony Forming Units (CFUs) for Staphylococcus aureus (A), Enterococcus faecalis (B), Escherichia coli (C), 
Pseudomonas aeruginosa (D), and Mycobacterium smegmatis (E) treated for two hours with varying concentrations of HME. 
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Figure 21: CFUs for Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, 
Escherichia coli, and Mycobacterium smegmatis Treated with HP 
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Figure 21. Colony Forming Units (CFUs) for Staphylococcus aureus (A), Enterococcus faecalis (B), Escherichia coli (C), 
Pseudomonas aeruginosa (D), and Mycobacterium smegmatis (E) treated for two hours with varying concentrations of HP. 
 
 
 
 
% Inhibition of Curcumin, HME, and HP 
 
CFU data collected for curcumin, HME, and HP treated bacteria was used to calculate % 
C
FU
s/
1
0
^4
 
C
FU
s/
1
0
^4
 
C
FU
s/
1
0
^4
 
C
FU
s/
1
0
^4
 
C
FU
s/
1
0
^6
 
46 
 
inhibition. Each run for each of the five bacteria was averaged to make these calculations. % 
inhibition was calculated using the formula % Inhibition= (Control-Treatment)/Control X 
100. This was calculated for each of the five bacteria at each treatment concentration (25 μM, 50 
μM, and 100 μM) for all compounds. Graphs were made all bacteria for all compounds. When 
comparing % inhibition data for bacteria treated with curcumin (Figure 22, Table 1) with 
bacteria treated with HME (Figure 23, Table 2), curcumin was found to have an overall higher % 
inhibition than HME. The % inhibition for S. aureus treated with curcumin was almost 99% for 
all three concentrations (Figure 22A), and % inhibition values for E. faecalis treated with 
curcumin (Figure 22B) were between 96 and 98%. The % inhibition values for E. coli treated 
with curcumin ranged between 71% and 97%, while the % inhibition values for P. aeruginosa 
treated with curcumin ranged from 83% to 92%. While HME was at least somewhat effective on 
each of the microorganisms, the % inhibition values overall were lower than they were for 
curcumin treated bacteria. The % inhibition values for S. aureus were all at 99% (Figure 23A), 
but the % inhibition values of E. faecalis, E. coli, and P. aeruginosa were less impressive (23B, 
23C, 23D). It appeared to be least effective on E. faecalis, whose % inhibition values only 
ranged from about 49% to 60%. For HP, % inhibition values overall were very low, with almost 
all values for all bacteria besides M. smegmatis falling under 50% (Figure 24, Table 3). HME 
produced significantly higher % inhibition values than HP. 
Overall, % inhibition values for all three compounds showed that while both curcumin and 
HME are highly effective at preventing colony forming units, HP is not. Curcumin worked on all 
bacteria but M. smegmatis, HME worked on all five bacteria, and HP only worked on M. 
smegmatis. The ability of hispolon derivatives to work so well on M. smegmatis so well sets it 
apart from curcumin, which appears to work well against gram positive and gram negative 
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bacteria but not against acid-fast bacteria. Values for curcumin were highest for gram positive 
 
bacteria, while HME did not have a pattern based on cell wall composition. 
Figure 22: % Inhibition for Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, 
Escherichia coli, and Mycobacterium smegmatis Treated with Curcumin 
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Table 1. % Inhibition Calculations for Curcumin Treated Bacteria 
 
Bacteria % Inhibition 
Sa 25 μM 98.52 
Sa 50 μM 99.27 
Sa 100 μM 98.52 
Ef 25 μM 97.91 
Ef 50 μM 98.16 
Ef 100 μM 96.95 
Ec 25 μM 86.42 
Ec 50 μM 71.44 
Ec 100 μM 97.11 
Pa 25 μM 83.41 
Pa 50 μM 88.43 
Pa 100 μM 92.28 
Ms 25 µM 0 
Ms 50 µM 0 
Ms 100 µM 0 
Table 1 shows the % inhibition calculations for bacteria treated with curcumin at each concentration based off of 
average CFU count. 
Figure 22. % inhibition calculations for Staphylococcus aureus (A), Enterococcus faecalis (B), Escherichia coli (C), Pseudomonas 
aeruginosa (D), and Mycobacterium smegmatis (E) treated for two hours with varying concentrations of curcumin. 
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Figure 23: % Inhibition for Staphylococcus aureus, Enterococcus faecalis, Pseudomonas 
aeruginosa, Escherichia coli, and Mycobacterium smegmatis Treated with HME 
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Figure 23. % inhibition calculations for Staphylococcus aureus (A), Enterococcus faecalis (B), Escherichia coli (C), 
Pseudomonas aeruginosa (D), and Mycobacterium smegmatis (E) treated for two hours with varying concentrations of 
HME. 
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Table 2. % Inhibition Calculations for HME Treated Bacteria 
 
Bacteria % Inhibition 
Sa 25 μM 99.71 
Sa 50 μM 99.71 
Sa 100 μM 99.43 
Ef 25 μM 49.34 
Ef 50 μM 78.19 
Ef 100 μM 60 
Ec 25 μM 72.55 
Ec 50 μM 67.77 
Ec 100 μM 72.17 
Pa 25 μM 85.67 
Pa 50 μM 59 
Pa 100 μM 86.87 
Ms 25 µM 97 
Ms 50 µM 97.1 
Ms 100 µM 97.4 
Table 2 shows the % inhibition calculations for bacteria at each concentration based off of average CFU count. 
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Figure 24: % Inhibition for Staphylococcus aureus, Enterococcus faecalis, Pseudomonas 
aeruginosa, Escherichia coli, and Mycobacterium smegmatis Treated with HP 
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Figure 24. % inhibition calculations for Staphylococcus aureus (A), Enterococcus faecalis (B), Escherichia coli (C), 
Pseudomonas aeruginosa (D), and Mycobacterium smegmatis (E) treated for two hours with varying concentrations of 
HP. 
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Table 3. % Inhibition Calculations for HP Treated Bacteria 
 
Bacteria % Inhibition 
Sa 25 μM 15.4 
Sa 50 μM 36 
Sa 100 μM 0 
Ef 25 μM 27 
Ef 50 μM 9 
Ef 100 μM 33 
Ec 25 μM 11 
Ec 50 μM 0 
Ec 100 μM 29 
Pa 25 μM 47 
Pa 50 μM 54 
Pa 100 μM 54 
Ms 25 µM 64.4 
Ms 50 µM 74.4 
Ms 100 µM 89 
Table 3 shows the % inhibition calculations for bacteria at each concentration based off of average CFU count. 
 
 
 
 
 
Evaluation of the Effect of Curcumin and HME on the Growth of Bacteria 
 
Growth was monitored for S. aureus, E. faecalis, P. aeruginosa, E. coli, and M. smegmatis to 
see if curcumin and HME had effects on bacterial growth. This examined growth of each 
microorganism with no treatment in order to compare the growth of the untreated 
microorganisms to the growth of the same microorganisms treated with curcumin and HME. A 
48 well plate was used to include all samples. For this experiment, readings were taken every 
hour for ten hours. One last reading was taken after twenty-four hours. In the same plate as the 
untreated bacteria, the same microorganisms were treated with curcumin and with HME. The 
treated bacteria were expected to have slower growth than the untreated bacteria, if any steady 
growth at all. This was measured in optical density (OD) at 600 nm. Three runs were carried out 
for each microorganism in this study, for both treated and untreated bacteria. The average OD 
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values throughout the ten hours were graphed for each microorganism under each of the three 
conditions. It must be noted that although all of the microorganisms were diluted to an initial 0.1 
OD before being plated, curcumin is very heavily pigmented and affects OD readings, despite 
normalization, making the starting OD of curcumin bacteria higher than untreated or HME 
treated bacteria. 
a. Staphylococcus aureus 
 
Staphylococcus aureus exhibited normal growth when untreated, shown by Figure 25. 
OD increased steadily throughout the ten hour period, starting at an OD reading around 
0.2 and finishing at around 0.6. For the curcumin treated S. aureus, OD remained nearly 
stagnant for the ten hour period after dropping slightly initially, and HME treated S. 
aureus showed no growth and a steadier decrease in OD over the ten hours. These results 
suggest that both curcumin and HME have antibacterial effects against S. aureus growth. 
Figure 25: Growth Curve for Treated and Untreated Staphylococcus aureus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Average OD with standard deviation for untreated, curcumin treated, and HME treated 
Staphylococcus aureus. 
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b. Enterococcus faecalis 
 
Enterococcus faecalis is a slower growing microorganism, and growth for the untreated 
bacteria over the ten hour reading period was less than for the other microorganisms used 
in this study (Figure 26). A very long lag phase of around 6 hours was observed. OD for 
E. faecalis treated with curcumin dropped initially and then remained stagnant. E. 
faecalis treated with HME did not see much of a change in OD over time. The results 
indicated that the growth was inhibited by both curcumin and HME. 
Figure 26: Growth Curve of Treated and Untreated Enterococcus faecalis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Average OD with standard deviation for untreated, curcumin treated, and HME treated Enterococcus 
faecalis. 
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OD over time. The results indicated that curcumin did have some effect against E. coli, 
and that HME was able to completely inhibit the growth of the bacteria. 
Figure 27: Growth Curve of Treated and Untreated Escherichia coli 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. Average OD with standard deviation for untreated, curcumin treated, and HME treated Escherichia coli. 
d. Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa had significantly increasing OD over the ten hour reading 
period when untreated (Figure 28). P. aeruginosa treated with curcumin did have a small 
increase in OD, and it seemed that curcumin was unable to completely inhibit the growth 
of this bacteria, although it was less than the control. However, P. aeruginosa treated 
with HME had a decrease in OD overtime. 
 
 
 
 
 
 
 
 
Figure 28: Growth Curve of Treated and Untreated Pseudomonas aeruginosa 
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Figure 28. Average OD with standard deviation for untreated, curcumin treated, and HME treated Pseudomonas 
aeruginosa. 
e. Mycobacterium smegmatis 
 
Mycobacterium smegmatis had significant OD growth for both the untreated and curcumin 
treated bacteria, with both ODs increasing by about 0.5-0.6 (Figure 29). This was expected, since 
none of these experiments have found curcumin to be overly effective against M. smegmatis. In 
contrast, M. smegmatis treated with HME did not see an OD increase at all, and instead saw OD 
decrease over the ten hour period. This suggests that while curcumin is not effective against M. 
smegmatis, HME is significantly effective. 
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Figure 29: Growth Curve for Treated and Untreated Mycobacterium smegmatis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Average OD with standard deviation for untreated, curcumin treated, and HME treated Mycobacterium 
smegmatis. 
Overall, both compounds do inhibit bacterial growth. HME inhibited the growth of all bacteria, 
including M. smegmatis. Curcumin was unable to stop M. smegmatis growth, but it did 
significantly stop S. aureus and E. faecalis. The growth of E. coli and P. aeruginosa was still less 
than the growth of the controls, but more than that of the gram positive curcumin treated 
bacteria. This experiment suggests that curcumin works better on gram positive bacteria than on 
gram negative bacteria, while HME is indiscriminate. 
Determining the Effect of Curcumin and HME on Biofilms 
 
a. Congo Red Assay 
 
After curcumin and HME were determined to be very effective against most of the bacteria 
used in this study, both compounds were tested against biofilms formed by S. aureus, E. faecalis, 
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utilized for one portion of the experiment. Four wells were used for each of the five 
microorganisms: a negative control, the untreated microorganism, the microorganism treated 
with 50 µM curcumin, and the microorganism treated with 50 µM HME. Plates were incubated 
and checked every 24 hours for 72 hours (Figure 30). The results after the full 72 hours suggest 
that curcumin does have some effectiveness against biofilm formation, but it does not stop 
bacterial growth completely. However, bacteria treated with curcumin did not form full biofilms 
like untreated bacteria did. The results regarding HME for this test were less conclusive, and 
based on the results of this experiment it cannot be concluded with certainty that HME plays a 
role in stopping biofilm growth. This suggests further studies need to be carried out to determine 
whether or not HME is successful against biofilms. 
 
Figure 30: Congo Red Biofilm Evaluation of S. aureus, E. faecalis, P. aeruginosa, E. coli, 
and M. smegmatis Untreated, Treated with Curcumin, and Treated with HME 
 
Figure 30. Biofilm assessment on a Congo Red plate after 72 hours for S. aureus (1-4), M. smegmatis (5-8), E. 
faecalis (9-12), E. coli (13-16), and P. aeruginosa (17-20). 
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b. Crystal Violet Assay 
 
A crystal violet (CV) assay was also done to evaluate the effectiveness of 50 µM curcumin and 
HME treatments on biofilms. The results of this assay were slightly more conclusive than the 
Congo Red assay (Figure 31). However, % inhibition values (Table 4) were not overly 
impressive for either curcumin or HME. Crystal violet was allowed to soak in each well for a 
half hour before the stain was removed and the 48 well plate was left at room temperature for 24 
hours. Biofilm growth was measured in OD (nm) after 1 ml of acetic acid was added to each well 
of the 48 well plate. If the compound was successful in biofilm inhibition, the OD would be 
higher for the untreated biofilm than for the treated biofilms. For this assay, curcumin was shown 
to inhibit biofilm formation in S. aureus, E. faecalis, and E. coli. It did not appear to inhibit 
biofilm formation in P. aeruginosa and M. smegmatis. HME worked well in inhibiting biofilm 
formation in S. aureus, M. smegmatis, E. coli, and P. aeruginosa, but not E. faecalis. Overall, % 
inhibition values (Table 4) are higher for HME than for curcumin. For example, S. aureus had 
values of 55% inhibition for curcumin and 85% inhibition for HME. Values for E. coli were 
about the same (roughly 39-40%) for both compounds. For M. smegmatis, there was no 
inhibition for curcumin and about 33% inhibition for HME. These results are mostly consistent 
with previous results in this study for both compounds, except for the failure of curcumin to 
inhibit the P. aeruginosa biofilm. Further studies are needed to reach definitive conclusions on 
the effects of these compounds against biofilms. 
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Figure 31: Measuring the Effectiveness of Curcumin and HME on Biofilms through a 
Crystal Violet Assay 
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Figure 31. Crystal Violet Assay shows average optical density (OD) of biolfims formed by Staphylococcus aureus 
(A), Enterococcus faecalis (B), Escherichia coli (C), Pseudomonas aeruginosa (D), and Mycobacterium smegmatis 
untreated, treated with 50 µM of curcumin and treated with 50 µM of HME. 
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Table 4. % Inhibition Values for Crystal Violet Assay 
 
Bacteria C % Inhibition HME % Inhibition 
Sa 55 85 
Ef 7.4 0 
Ec 40.1 39 
Pa 0 6.2 
Ms 0 33 
Table 4 shows % inhibition values from the CV assay for curcumin and HME. 
c. Resazurin Assay 
 
A resazurin assay was also done to determine if 50 µM curcumin and HME treatments are 
effective against biofilms. This assay also involved the use of a 48 well plate. About 24 hours 
before the reading was taken, 1X PBS and 20 µM resazurin were added to each well. 
Fluorescence was measured through reflective light units (RLUs) at 560 nm excitation and 590 
nm emission. Of the three biofilm assays conducted, the results of the resazurin assay were the 
most promising. If the compound was successful in biofilm inhibition, the RLUs would be higher 
for the untreated biofilm than for the treated biofilms. This assay showed curcumin being 
effective against S. aureus, E. faecalis, E. coli, and P. aeruginosa biofilms, but not against M. 
smegmatis biofilms. HME reduced biofilm growth in all five microorganisms in comparison to 
the untreated biofilms (Figure 32). However, % inhibition values (Table 5) are still significantly 
lower than % inhibition values for the CFU assays. For this assay, E. faecalis biofilms were 
inhibited by both compounds, but % inhibition values were around 51% for curcumin compared 
to only 14% for HME. Values for E. coli and P. aeruginosa were similar. The results for the 
three different biofilm assays were not overly conclusive, and poor inhibition suggests biofilms 
are harder to treat than individual CFUs. 
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Figure 32: Measuring the Effectiveness of Curcumin and HME on Biofilms through a 
Resazurin Assay 
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Figure 32. Fluorescence was measured at an excitation of 560 nm and an emission of 590 nm for Staphylococcus 
aureus (A), Enterococcus faecalis (B), Escherichia coli (C), Pseudomonas aeruginosa (D), and Mycobacterium 
smegmatis (E) biofilms that were untreated, treated with 50 µM curcumin, and 50 µM HME. 
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Table 5. % Inhibition Values for Resazurin Assay 
 
 
Bacteria 
C % 
Inhibition 
 
HME % Inhibition 
Sa 15.3 19.3 
Ef 51.2 14 
Ec 44 30 
Pa 45 52 
Ms 0 19 
Table 5 shows % inhibition values from the Resazurin assay for curcumin and HME. 
Overall the CV and Resazurin assay showed more promise than the Congo Red Assay. Due to 
the unimpressive results for all three, however, it is clear that biofilms are difficult to treat and 
that higher concentrations of the compounds may be required. These experiments should be 
repeated with higher concentrations. 
 
 
 
Live-Dead Assay Through Fluorescent Microscopy 
 
Live-Dead assays were done on each of the five microorganisms to compare the number of live 
and dead cells in the control, curcumin treated, and HME treated samples. Stock plates were 
prepared for each of the five bacteria and incubated overnight at 37°C. Tubes were prepared for 
two hour treatments of both 50 µM curcumin and 50 µM HME. Slides were prepared with a 
loopful of bacteria and 5 µl of a 60 Green: 40 Red Live-Dead dye and viewed under the 
fluorescent microscope at 40X. 
a. Staphylococcus aureus 
 
All slides were viewed under the fluorescent microscope at 40X. The control slide for S. 
aureus showed mostly green, or living, cells, as would be expected in the control (Figure 33). 
Treated slides for curcumin and HME suggested the treatments were successful, as the cells were 
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mostly red compared to the control’s mostly green cells. This assay shows that both compounds 
resulted in heavy death of S. aureus. 
Figure 33: Live-Dead Assay for Staphylococcus aureus 
 
 
Figure 33. Live-Dead Assay of Staphylococcus aureus untreated (A), treated with curcumin (B), and treated 
with HME (C). 
 
 
b. Enterococcus faecalis 
 
All slides were viewed under the fluorescent microscope at 40X. The control slide for E. 
faecalis showed mostly green cells, suggesting that most of the cells were alive, as they were 
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expected to be (Figure 34). Treated slides for curcumin and HME suggested the treatments were 
successful, as the cells were mostly red compared to the control’s mostly green cells. This assay 
shows that both compounds resulted in significant death of E. faecalis. 
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Figure 34: Live-Dead Assay for Enterococcus faecalis 
 
 
Figure 34. Live-Dead Assay of Enterococcus faecalis untreated (A), treated with curcumin (B), and treated 
with HME (C). 
 
c. Escherichia coli 
 
All slides were viewed under the fluorescent microscope at 40X. The control for E. coli 
showed most green cells, which was expected. Both curcumin and HME treated E. coli resulted 
in mostly red cells, and there were very few green cells, especially compared to the untreated 
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sample (Figure 35). These results suggest that both compounds have at least some effectivity 
against E. coli. 
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Figure 35: Live-Dead Assay of Escherichia coli 
 
 
Figure 35. Live-Dead Assay of Escherichia coli untreated (A), treated with curcumin (B), and treated with HME 
(C). 
 
d. Pseudomonas aeruginosa 
 
All slides were viewed under the fluorescent microscope at 40X. The control for P. 
aeruginosa, like the other controls, showed mostly green cells. Both curcumin treated and HME 
treated P. aeruginosa showed mostly red cells under the microscope (Figure 36). This shows that 
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both compounds are at least moderately effective against P. aeruginosa, compared to how many 
living cells were present in the untreated sample. 
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Figure 36: Live-Dead Assay of Pseudomonas aeruginosa 
 
 
 
Figure 36. Live-Dead Assay of Pseudomonas aeruginosa untreated (A), treated with curcumin (B), and treated 
with HME (C). 
e. Mycobacterium smegmatis 
 
All slides were viewed under the fluorescent microscope at 40X. The control for M. smegmatis 
showed mostly green cells. Consistent with results from previous experiments, the curcumin 
treated M. smegmatis did still have a significant number of green cells, especially compared to 
71 
 
the HME treated M. smegmatis, where the cells were almost all red (Figure 37). This shows that 
HME works much better on M. smegmatis than curcumin, which does not work well on this 
specific bacterium at all. 
Figure 37: Live-Dead Assay of Mycobacterium smegmatis 
 
 
Figure 37. Live-Dead Assay of Mycobacterium smegmatis untreated (A), treated with curcumin (B), and treated 
with HME (C). 
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The Live-Dead assays correlated with the results of the previous experiments, showing HME 
treatment to be effective against all five of the microorganisms and curcumin treatment to be 
effective against all of the microorganisms but M. smegmatis. This assay confirms that treatment 
with these compounds do result in bacterial cell death. 
 
 
 
4. Conclusions 
 
Curcumin 
 
The results of this study confirmed that curcumin is effective against not only S. aureus, but 
against E. faecalis, E. coli, and P. aeruginosa as well. The CFU assays showed the effectiveness 
of curcumin against S. aureus, E. faecalis, E. coli, and P. aeruginosa, but not against M. 
smegmatis. It can be concluded from these results that curcumin is effective against both gram 
positive and gram negative bacteria, but not against acid-fast bacteria. Overall, the % inhibition 
values were higher for gram positive bacteria treated with curcumin than for gram negative 
bacteria treated with curcumin. Gram negative bacteria are more likely to exhibit resistance to 
antibacterial compounds due to an extra cell membrane that gram positive bacteria do not 
possess (Zgurskaya et al., 2016). However, all % inhibition calculations showed significant 
inhibition in all microorganisms treated with curcumin besides M. smegmatis. 
The growth curve confirmed curcumin to be somewhat effective against all of the bacteria used 
in this study except for M. smegmatis. OD values decreased for curcumin treated S. aureus and 
E. faecalis, while they increased slightly for E. coli and P. aeruginosa. For M. smegmatis growth 
occurred at a similar rate for treated and untreated bacteria. Curcumin’s effectiveness was also 
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shown by the Live-Dead assays done for each microorganism, which showed mostly green, 
living cells for the control bacteria and mostly red, dead cells for the curcumin treated bacteria. 
Results for the Congo Red assay suggest that curcumin has some effectiveness against 
biofilms, but that it does not stop biofilm growth completely. This is corroborated by data 
collected from the Crystal Violet (CV) assay. The Resazurin assay offered more conclusive 
results for the potential effect of curcumin on biofilms. These assays both showed that while 
curcumin did have some effect against the biofilms formed by the microorganisms besides M. 
smegmatis, it did not produce overwhelming % inhibition like it did in the CFU assays. This 
study therefore indicated that biofilms are harder to treat than individual CFUs are, and in future 
experiments, the concentration used to treat biofilms may need to be higher than 50 µM. 
Biofilms are known to be harder to treat than singular bacterial colonies, and they are more likely 
to be antibiotic resistant as well (Hughes & Webber, 2017). The results in this study regarding 
curcumin’s antibacterial effects correlate with results from previous studies regarding the 
antibacterial effects of curcumin when used on various types of gram negative and gram positive 
bacteria. The results also suggest that curcumin is most effective on gram positive bacteria, 
moderately effective on gram negative bacteria, and not effective on acid-fast bacteria. 
HME 
 
Currently, whether or not hispolon will be a widely effective antibacterial agent is not yet well 
known, although the results of this study were promising. The results of the CFU assays suggest 
that HME is at least somewhat effective against the growth of all five microorganisms, including 
M. smegmatis. Compared to curcumin, however, % inhibition values were slightly lower for all 
bacteria besides S. aureus and M. smegmatis. Unlike with curcumin, HME does not seem to 
work best specifically on one type of cell wall compared to others. 
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In addition, the growth curve confirmed HME to be at least somewhat effective against all five 
bacteria used in the study. For all HME treated bacteria, OD values decreased throughout the 10 
hour reading period, compared to the increase in OD values in all of the untreated bacteria. HME 
works especially well against M. smegmatis compared to curcumin. HME’s effectiveness was 
also shown by the Live-Dead assays done for each microorganism, which showed mostly green, 
living cells for the control bacteria and mostly red, dead cells for the HME treated bacteria. 
However, much future research is needed to determine if in fact hispolon derivatives will ever be 
a viable option to treating bacterial infections. 
Similarly to curcumin, HME did not seem to tremendously inhibit the biofilms based on 
calculated % inhibition values. The Resazurin assay offered the most promising results, but the 
biofilm assays were not as successful as the colony forming unit assays. This study indicated that 
biofilms are harder to treat than individual CFUs, and in future experiments, the concentration 
used to treat biofilms may need to be higher than 50 µM. As previously stated, biofilms are 
expected to be more difficult to treat (Hughes & Webber, 2017). Future experiments should also 
include testing hispolon and antibiotics together against biofilms to see if results are improved. 
HP 
 
Given the overall success of HME against the various bacteria used in this study, HP was 
tested as well to see if a second hispolon derivative would yield the same results. Like HME, HP 
has been shown to be effective against Mycobacterium (Balaji et al., 2019). However, just from 
the results of the CFU assays for this compound, it is clear that HP does not have the same 
antibacterial effect against gram positive and negative bacteria that it does against acid-fast 
bacteria. The CFU graphs shows very little, if any inhibition, for any of the bacteria besides M. 
smegmatis. For S. aureus, E. faecalis, P. aeruginosa, and E. coli, the treated plates all have just 
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as much, if not more, growth as the control plates. M. smegmatis had % inhibition numbers of 
85% or above for all three concentrations, while the % inhibition numbers for all other bacteria 
was 54% or below. In some cases, treated plates had more growth than the control plates, 
resulting in an inhibition value of zero. It is possible that while HME has the ability to prevent 
mycolic acid synthesis and affect the cell walls of gram negative and gram positive bacteria, HP 
may only prevent mycolic acid synthesis (Balaji et al., 2016, Balaji et al., 2019). Due to the 
unsuccessful CFU assays, other experiments were not completed for this compound as they were 
for HME and curcumin. This compound only appeared to work on M. smegmatis. 
Overall Conclusions 
 
In conclusion, curcumin and HME look to be effective antibacterial agents against various 
types of gram positive, gram negative, and in the case of HME, acid-fast bacteria. Based on the 
results of this study, curcumin appears to be most effective on gram positive bacteria than gram 
negative bacteria, which is often the case for various antibacterial treatments (Zgurskaya et al., 
2016). It does not seem to be effective against acid-fast bacteria. HME, however, appears to be 
effective against gram positive, gram negative, and acid-fast bacteria. It is overall more effective 
against the gram negative bacteria than curcumin was, and definitely more effective on acid-fast 
bacteria. HP, while effective on acid-fast bacteria, did not show much promise of being effective 
against gram negative or gram positive bacteria. 
Future Studies 
 
Some relevant future studies may include investigating more of the many hispolon derivatives 
as antibacterial agents, as well as exploring the effectiveness of both curcumin and hispolon 
derivatives in concert with antibiotics. Curcumin and HME should be tested at concentrations 
above 50 µM for biofilm activity, and once again, in synergy with antibiotics to determine if that 
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improves their effectiveness. Based on the results of this study, both curcumin and HME are 
promising as future antibacterial treatments. 
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